Annual EBITDA
-$32.45 M
+$26.28 M+44.75%
March 31, 2024
Summary
- As of February 24, 2025, VTGN annual EBITDA is -$32.45 million, with the most recent change of +$26.28 million (+44.75%) on March 31, 2024.
- During the last 3 years, VTGN annual EBITDA has fallen by -$15.01 million (-86.07%).
- VTGN annual EBITDA is now -381700.00% below its all-time high of -$8500.00, reached on December 31, 2010.
Performance
VTGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$14.96 M
-$889.00 K-6.32%
December 31, 2024
Summary
- As of February 24, 2025, VTGN quarterly EBITDA is -$14.96 million, with the most recent change of -$889.00 thousand (-6.32%) on December 31, 2024.
- Over the past year, VTGN quarterly EBITDA has dropped by -$2.98 million (-24.87%).
- VTGN quarterly EBITDA is now -2920.32% below its all-time high of $530.40 thousand, reached on December 31, 2013.
Performance
VTGN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$52.22 M
-$7.22 M-16.04%
December 31, 2024
Summary
- As of February 24, 2025, VTGN TTM EBITDA is -$52.22 million, with the most recent change of -$7.22 million (-16.04%) on December 31, 2024.
- Over the past year, VTGN TTM EBITDA has dropped by -$14.65 million (-38.98%).
- VTGN TTM EBITDA is now -2373581.82% below its all-time high of -$2200.00, reached on March 31, 2007.
Performance
VTGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
VTGN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +44.8% | -24.9% | -39.0% |
| 3 y3 years | -86.1% | -24.9% | -39.0% |
| 5 y5 years | -32.5% | -24.9% | -39.0% |
VTGN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -86.1% | +44.8% | -125.3% | +23.8% | -60.9% | +18.1% |
| 5 y | 5-year | -86.1% | +44.8% | -384.2% | +23.8% | -257.7% | +18.1% |
| alltime | all time | <-9999.0% | +44.8% | -2920.3% | +65.7% | <-9999.0% | +35.9% |
VistaGen Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | -$14.96 M(+6.3%) | -$52.22 M(+16.0%) |
| Sep 2024 | - | -$14.07 M(+17.4%) | -$45.00 M(+19.8%) |
| Jun 2024 | - | -$11.98 M(+6.8%) | -$37.57 M(+15.8%) |
| Mar 2024 | -$32.45 M(-44.7%) | -$11.21 M(+44.8%) | -$32.45 M(-2.7%) |
| Dec 2023 | - | -$7.74 M(+16.6%) | -$33.34 M(-5.4%) |
| Sep 2023 | - | -$6.64 M(-3.2%) | -$35.24 M(-23.3%) |
| Jun 2023 | - | -$6.86 M(-43.3%) | -$45.95 M(-21.8%) |
| Mar 2023 | -$58.74 M(+24.8%) | -$12.10 M(+25.6%) | -$58.73 M(-7.0%) |
| Dec 2022 | - | -$9.63 M(-44.5%) | -$63.18 M(-0.9%) |
| Sep 2022 | - | -$17.36 M(-11.6%) | -$63.77 M(+7.9%) |
| Jun 2022 | - | -$19.64 M(+18.6%) | -$59.07 M(+25.6%) |
| Mar 2022 | -$47.05 M(+169.8%) | -$16.55 M(+62.0%) | -$47.05 M(+28.7%) |
| Dec 2021 | - | -$10.22 M(-19.3%) | -$36.57 M(+16.0%) |
| Sep 2021 | - | -$12.66 M(+66.3%) | -$31.53 M(+43.6%) |
| Jun 2021 | - | -$7.61 M(+25.3%) | -$21.96 M(+25.9%) |
| Mar 2021 | -$17.44 M(-15.6%) | -$6.08 M(+17.4%) | -$17.44 M(+19.5%) |
| Dec 2020 | - | -$5.18 M(+67.6%) | -$14.60 M(-4.9%) |
| Sep 2020 | - | -$3.09 M(-0.2%) | -$15.36 M(-12.6%) |
| Jun 2020 | - | -$3.10 M(-4.3%) | -$17.57 M(-14.9%) |
| Mar 2020 | -$20.65 M(-15.7%) | -$3.24 M(-45.5%) | -$20.65 M(-10.6%) |
| Dec 2019 | - | -$5.93 M(+11.8%) | -$23.11 M(-5.1%) |
| Sep 2019 | - | -$5.31 M(-14.1%) | -$24.37 M(-7.9%) |
| Jun 2019 | - | -$6.18 M(+8.5%) | -$26.47 M(+8.1%) |
| Mar 2019 | -$24.49 M(+77.1%) | -$5.70 M(-20.8%) | -$24.49 M(+1.3%) |
| Dec 2018 | - | -$7.19 M(-3.0%) | -$24.18 M(+23.6%) |
| Sep 2018 | - | -$7.41 M(+76.6%) | -$19.56 M(+16.1%) |
| Jun 2018 | - | -$4.19 M(-22.1%) | -$16.84 M(+13.1%) |
| Mar 2018 | -$13.83 M(+41.6%) | -$5.39 M(+109.5%) | -$14.88 M(+23.7%) |
| Dec 2017 | - | -$2.57 M(-45.2%) | -$12.03 M(+2.7%) |
| Sep 2017 | - | -$4.69 M(+109.6%) | -$11.71 M(+16.1%) |
| Jun 2017 | - | -$2.24 M(-11.6%) | -$10.09 M(+3.4%) |
| Mar 2017 | -$9.77 M(-78.9%) | -$2.53 M(+12.2%) | -$9.77 M(-80.8%) |
| Dec 2016 | - | -$2.26 M(-26.5%) | -$50.82 M(+0.2%) |
| Sep 2016 | - | -$3.07 M(+60.7%) | -$50.70 M(-7.2%) |
| Jun 2016 | - | -$1.91 M(-95.6%) | -$54.64 M(-33.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | -$46.39 M(+403.8%) | -$43.59 M(+1944.7%) | -$81.49 M(+95.4%) |
| Dec 2015 | - | -$2.13 M(-69.6%) | -$41.69 M(+4.7%) |
| Sep 2015 | - | -$7.01 M(-75.6%) | -$39.83 M(+16.5%) |
| Jun 2015 | - | -$28.76 M(+658.0%) | -$34.20 M(+271.4%) |
| Mar 2015 | -$9.21 M(+582.8%) | -$3.79 M(+1341.1%) | -$9.21 M(+37.4%) |
| Dec 2014 | - | -$263.30 K(-80.9%) | -$6.70 M(+13.4%) |
| Sep 2014 | - | -$1.38 M(-63.4%) | -$5.91 M(+5.1%) |
| Jun 2014 | - | -$3.77 M(+193.1%) | -$5.62 M(+317.0%) |
| Mar 2014 | -$1.35 M(-88.6%) | -$1.29 M(-342.5%) | -$1.35 M(-61.1%) |
| Dec 2013 | - | $530.40 K(-148.5%) | -$3.46 M(-61.5%) |
| Sep 2013 | - | -$1.09 M(-317.9%) | -$9.00 M(-6.3%) |
| Jun 2013 | - | $501.60 K(-114.7%) | -$9.61 M(-18.4%) |
| Mar 2013 | -$11.85 M(+15.4%) | -$3.40 M(-32.1%) | -$11.78 M(-9.8%) |
| Dec 2012 | - | -$5.01 M(+194.3%) | -$13.06 M(+8.1%) |
| Sep 2012 | - | -$1.70 M(+2.6%) | -$12.08 M(-0.8%) |
| Jun 2012 | - | -$1.66 M(-64.6%) | -$12.17 M(-0.1%) |
| Mar 2012 | -$10.27 M(>+9900.0%) | -$4.69 M(+16.2%) | -$12.18 M(+62.4%) |
| Dec 2011 | - | -$4.03 M(+124.6%) | -$7.50 M(+116.2%) |
| Sep 2011 | - | -$1.80 M(+7.7%) | -$3.47 M(+107.0%) |
| Jun 2011 | - | -$1.67 M(>+9900.0%) | -$1.68 M(>+9900.0%) |
| Mar 2011 | - | -$5200.00(+188.9%) | -$11.00 K(+29.4%) |
| Dec 2010 | -$8500.00(-60.5%) | -$1800.00(-10.0%) | -$8500.00(+6.3%) |
| Sep 2010 | - | -$2000.00(0.0%) | -$8000.00(+11.1%) |
| Jun 2010 | - | -$2000.00(-25.9%) | -$7200.00(0.0%) |
| Mar 2010 | - | -$2700.00(+107.7%) | -$7200.00(-66.7%) |
| Dec 2009 | -$21.50 K(+31.9%) | -$1300.00(+8.3%) | -$21.60 K(-34.9%) |
| Sep 2009 | - | -$1200.00(-40.0%) | -$33.20 K(+3.4%) |
| Jun 2009 | - | -$2000.00(-88.3%) | -$32.10 K(+2.9%) |
| Mar 2009 | - | -$17.10 K(+32.6%) | -$31.20 K(+91.4%) |
| Dec 2008 | -$16.30 K | -$12.90 K(>+9900.0%) | -$16.30 K(+379.4%) |
| Sep 2008 | - | -$100.00(-90.9%) | -$3400.00(+3.0%) |
| Jun 2008 | - | -$1100.00(-50.0%) | -$3300.00(-26.7%) |
| Mar 2008 | - | -$2200.00(-4.3%) | -$4500.00(0.0%) |
| Jun 2007 | - | -$2300.00(+4.5%) | -$4500.00(+104.5%) |
| Mar 2007 | - | -$2200.00 | -$2200.00 |
FAQ
- What is VistaGen Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual EBITDA year-on-year change?
- What is VistaGen Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly EBITDA year-on-year change?
- What is VistaGen Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for VistaGen Therapeutics?
- What is VistaGen Therapeutics TTM EBITDA year-on-year change?
What is VistaGen Therapeutics annual EBITDA?
The current annual EBITDA of VTGN is -$32.45 M
What is the all time high annual EBITDA for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual EBITDA is -$8500.00
What is VistaGen Therapeutics annual EBITDA year-on-year change?
Over the past year, VTGN annual EBITDA has changed by +$26.28 M (+44.75%)
What is VistaGen Therapeutics quarterly EBITDA?
The current quarterly EBITDA of VTGN is -$14.96 M
What is the all time high quarterly EBITDA for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly EBITDA is $530.40 K
What is VistaGen Therapeutics quarterly EBITDA year-on-year change?
Over the past year, VTGN quarterly EBITDA has changed by -$2.98 M (-24.87%)
What is VistaGen Therapeutics TTM EBITDA?
The current TTM EBITDA of VTGN is -$52.22 M
What is the all time high TTM EBITDA for VistaGen Therapeutics?
VistaGen Therapeutics all-time high TTM EBITDA is -$2200.00
What is VistaGen Therapeutics TTM EBITDA year-on-year change?
Over the past year, VTGN TTM EBITDA has changed by -$14.65 M (-38.98%)